Altay Therapeutics

Altay Therapeutics develops small molecule drugs aimed at treating chronic liver diseases such as liver fibrosis and liver cancer. The company leverages over 70 years of combined experience in small molecule drug development to address conditions affecting over 20 million Americans, representing a market size exceeding $30 billion. Altay Therapeutics has demonstrated promising pre-clinical results in mouse models, showing not only a reduction in fibrosis but also a reversal of fibrotic tissue back to normal tissue. The developmental strategy aims for a clinic-ready compound by the end of 2021, with plans to enter phase I clinical trials by mid-2022.